Overview

NCI Definition: This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a myeloproliferative neoplasm, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative neoplasm category. (WHO, 2001) [1]

Myelodysplastic/myeloproliferative neoplasm, unclassifiables most frequently harbor alterations in ASXL1, JAK2, U2AF1, TET2, and SRSF2 [2].

Most Commonly Altered Genes in Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

ASXL1fs, JAK2 V617F, JAK2 Mutation, JAK2 Exon 14 Mutation, and U2AF1 Mutation are the most common alterations in myelodysplastic/myeloproliferative neoplasm, unclassifiable [2].

Top Alterations in Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Significant Genes in Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

ABL1 +

ASXL1 +

BCOR +

BCR +

CBL +

DEK +

EZH2 +

FLT3 +

KIT +

KMT2A +

KRAS +

MECOM +

NF1 +

NRAS +

NUP214 +

PTPN11 +

RIT1 +

RPN1 +

RUNX1 +

SF3B1 +

SRSF2 +

STAG2 +

TP53 +

U2AF1 +

ZRSR2 +

Disease Details

Synonyms
Mixed Myelodysplastic/Myeloproliferative Disease, Unclassifiable, Unclassifiable Myeloproliferative/Myelodysplastic Syndrome, MDS/MPN, Unclassifiable, MDS/MPD-U, MDS/MPD, U, MDS/MPN-U, MDS/MPN, U, Mixed Myeloproliferative/Myelodysplastic Syndrome, Unclassifiable, Unclassifiable Myelodysplastic/Myeloproliferative Disease, Myelodysplastic/Myeloproliferative Disease, Unclassifiable
Parent(s)
Myelodysplastic/Myeloproliferative Neoplasm
OncoTree Name
MDS/MPN, Unclassifiable
OncoTree Code
MDSMPNU

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.